Sage Therapeutics (NASDAQ:SAGE) Downgraded by StockNews.com

StockNews.com lowered shares of Sage Therapeutics (NASDAQ:SAGE) from a hold rating to a sell rating in a research report report published on Friday morning.

A number of other equities research analysts also recently weighed in on SAGE. Wedbush reissued a neutral rating and set a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. Royal Bank of Canada boosted their price target on Sage Therapeutics from $21.00 to $26.00 and gave the company a sector perform rating in a research note on Thursday, February 15th. Bank of America downgraded Sage Therapeutics from a neutral rating to an underperform rating and dropped their price target for the company from $24.00 to $14.00 in a research note on Wednesday, April 17th. Needham & Company LLC reaffirmed a hold rating on shares of Sage Therapeutics in a research note on Thursday, April 18th. Finally, Scotiabank dropped their price target on Sage Therapeutics from $34.00 to $19.00 and set a sector outperform rating for the company in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $39.28.

Sage Therapeutics Price Performance

Shares of NASDAQ:SAGE opened at $12.89 on Friday. The company has a market capitalization of $774.82 million, a price-to-earnings ratio of -1.42 and a beta of 0.86. The firm’s 50 day simple moving average is $19.64 and its 200 day simple moving average is $20.88. Sage Therapeutics has a fifty-two week low of $10.92 and a fifty-two week high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. During the same period last year, the company earned ($2.47) earnings per share. The firm’s revenue was up 2621.5% compared to the same quarter last year. Equities research analysts expect that Sage Therapeutics will post -6.3 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Hedge funds have recently made changes to their positions in the business. CWM LLC grew its holdings in Sage Therapeutics by 274.2% during the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 883 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Sage Therapeutics by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Sage Therapeutics by 17.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,375 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Sage Therapeutics during the 3rd quarter valued at about $219,000. Finally, Quest Partners LLC bought a new stake in shares of Sage Therapeutics during the 4th quarter valued at about $261,000. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.